ArticleFrontiers in immunology2025
Interleukin-6 levels and their haplotypes are associated with serological autoantibodies status and clinical activity in rheumatoid arthritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Interleukin-6 (IL-6) plays an important role in the pathogenesis, progression, and severity of rheumatoid arthritis (RA). High levels of IL-6 are involved in the maintenance of inflammation in the synovium and the development of new blood vessels in the inflamed synovium, contributing to pannus formation. In the present study, we aimed to investigate the relationship of IL-6 polymorphisms/ haplotypes with RA in Mexican patients and on circulating levels of IL-6 and the clinical features of the disease. Methods: A total of 225 patients with RA and 362 healthy controls were recruited. Patients' clinical features were collected, and inflammatory and serological parameters [anti-cyclic citrullinated peptides (anti-CCPs) and rheumatoid factor (RF)] were assessed. All subjects were genotyped for IL-6 polymorphisms (rs1800797, rs1800796, and rs1818879) using real-time polymerase chain reaction (PCR) with TaqMan probes. Circulating levels of IL-6 were measured by commercial ELISA (enzyme-linked immunosorbent assay) kits. Results and discussion: Our results show that the GGG haplotype of the IL-6 gene is associated with a serological status of double-positive autoantibodies [odds ratio (OR) = 2.09, p = 0.009], as well as with a double-positive high autoantibodies status (OR = 2.08, p = 0.04), although a marginal association was shown to RA susceptibility (OR = 1.34, p = 0.050). Polymorphisms and haplotypes were not associated with serum levels of IL-6. However, serum levels of IL-6 ≥27.6 pg/mL were associated with clinical features of RA severity, such as morning stiffness ≥30 min (OR = 1.83, p = 0.001), HAQ-DI ≥1 (OR = 2.73, p=0.009), DAS28-ESR ≥3.2 (OR = 3.63, p = 0.002), and hsCRP ≥10 mg/L (OR = 6.35, p < 0.001). This study provides evidence of the relationship between IL-6 haplotypes, circulating levels of IL-6, and clinical features and serological status to autoantibodies in patients with RA from Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.